Insider Buying: CytoMed Therapeutics (NASDAQ:GDTC) Director Purchases 112,000 Shares of Stock

CytoMed Therapeutics Limited (NASDAQ:GDTC) Director Chee Kong Choo bought 112,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $1.15 per share, with a total value of $128,800.00. Following the completion of the purchase, the director directly owned 430,324 shares in the company, valued at $494,872.60. This trade represents a 35.18% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

CytoMed Therapeutics Price Performance

GDTC stock opened at $1.14 on Monday. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.06. CytoMed Therapeutics Limited has a one year low of $0.68 and a one year high of $3.68. The company has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.16.

CytoMed Therapeutics (NASDAQ:GDTC) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Friday, April 10th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.